Öztürk C.Genel F.Aksu G.Bakiler A.R.Kütükçüler N.2019-10-272019-10-2720030010-01610010-0161https://hdl.handle.net/11454/22767Juvenile ankylosing spondylitis and inflammatory bowel disease rarely develop simultaneously, and the treatment of the disease with disease-modifying antirheumatic drugs might be difficult. In this report we present an eight-year old boy with juvenile ankylosing spondylitis and inflammatory bowel disease resistant to combined therapy of antirheumatismal drugs because of its rarity in childhood. Anti-tumor necrosis factor-? monoclonal antibody administration, a new biological treatment, is discussed in view of the literature.trinfo:eu-repo/semantics/closedAccessAnti-tumor necrosis factor-? monoclonal antibodyInflammatory bowel diseaseJuvenile ankylosing spondylitisAnti-tumor necrosis factor-alpha monoclonal antibody treatment in a case with persistent juvenile ankylosing spondylitis and inflammatory bowel disease [Jüvenil ankilozan spondilit ve enflamatuvar bagirsak hastaligi olan bir hastada anti-tümör nekrozis faktör-alfa monoklonal antikor tedavisi]Article463203206Q4